CND Life Sciences (CND) has made a significant announcement regarding the presentation of six abstracts related to the identification of phosphorylated alpha-synuclein (P-SYN) in cutaneous nerve fibers in the skin at the American Academy of Neurology 2024 Annual Meeting (AAN). The event will take place on April 13-18 in Denver at the Colorado Convention Center.
One of the abstracts highlights the first subgroup analysis from the Synuclein-One Study, an NIH-funded 30-site multicenter trial. Focused on patients with dementia with Lewy bodies (DLB) and mild cognitive impairment (MCI), this abstract has been selected as a 2024 Abstract of Distinction and will be presented during the Contemporary Clinical Issues Plenary Session by Christopher Gibbons, MD, Senior Scientific Advisor and Co-Founder of CND Life Sciences, and Professor of Neurology at Harvard Medical School on Monday, April 15 at 9:15 am MT.
Another abstract discusses the utility of the synuclein skin biopsy in the initial diagnosis and evaluation of Parkinsonian disorders in everyday clinical practice. This abstract will be presented during the Emerging Science 2 Session by Jonathan Ross Isaacson, MD, Neurophysiology Fellow at Beth Israel Deaconess Medical Center on Tuesday, April 16 at 5:36 p.m. MT.
Additional abstracts cover various topics, including a retrospective review of essential tremor patients with a clinical phenotype of ‘Parkinsons plus’, the utility of skin biopsy detection of P-SYN in patients with suspected drug-induced Parkinson’s with normal DaTscans, a summary of patients with pure autonomic failure (PAF) from the Synuclein-One Study, and a platform presentation unveiling CND’s NerValence™ technology enabling quantification of cutaneous phosphorylated alpha-synuclein using high-resolution, high-throughput confocal imaging combined with artificial intelligence-supported protein detection algorithms.
Dr. Gibbons emphasized the significance of these research findings in advancing diagnostic capabilities for neurodegenerative diseases. He highlighted the growing demand for accurate diagnostic tools and biomarkers to provide better care for patients.
Dr. Todd Levine, Chief Medical Officer of CND Life Sciences, underscored the importance of the data presented at the AAN meeting in showcasing the utility of the Syn-One Test® and its potential to revolutionize neurodegenerative disease diagnoses and support scientific research in the biopharma industry.
Details of relevant presentations, including abstract titles, lead authors, and presentation details, were provided to offer insight into the scope of research being presented at the AAN meeting.
CND Life Sciences, operating a CLIA-certified and CAP-accredited laboratory in Scottsdale, Arizona, supports patients facing potential diagnoses of neurodegenerative diseases and other neurological conditions. The company provides the Syn-One Test®, the world’s only commercially available test to detect, visualize, and quantify phosphorylated alpha-synuclein located in cutaneous nerves. Collaborating with biopharmaceutical companies on clinical trials, CND aims to advance the validation and clinical utility of its Syn-One Test in detecting synucleinopathies like Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy.
